426 related articles for article (PubMed ID: 8622102)
1. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
Covi M; Velluti G
J Chemother; 1995 Jun; 7 Suppl 2():137-42. PubMed ID: 8622102
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
Colardyn F
J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
Rodriguez-Noriega E; Esparza-Ahumada S; Morfin-Otero R
J Chemother; 1995 Jun; 7 Suppl 2():155-60. PubMed ID: 8622105
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
Beaucaire G
J Chemother; 1995 Jun; 7 Suppl 2():165-73. PubMed ID: 8622107
[TBL] [Abstract][Full Text] [Related]
5. Overview of the efficacy of isepamicin in the adult core clinical trial programme.
Carbon C
J Chemother; 1995 Jun; 7 Suppl 2():79-85. PubMed ID: 8622115
[TBL] [Abstract][Full Text] [Related]
6. A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients.
Viganò A; Principi N
J Chemother; 1995 Jun; 7 Suppl 2():95-101. PubMed ID: 8622117
[TBL] [Abstract][Full Text] [Related]
7. Isepamicin versus amikacin in the treatment of urinary tract infection.
Sturm W
J Chemother; 1995 Jun; 7 Suppl 2():149-54. PubMed ID: 8622104
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections.
Leal del Rosal P
J Chemother; 1995 Jun; 7 Suppl 2():143-8. PubMed ID: 8622103
[TBL] [Abstract][Full Text] [Related]
9. Once daily isepamicin treatment in complicated urinary tract infections.
Lee SS; Liu YC; Wann SR; Lin WR; Tsai TH; Lin HH; Chen YS; Yen MY
J Microbiol Immunol Infect; 1999 Jun; 32(2):105-10. PubMed ID: 11561574
[TBL] [Abstract][Full Text] [Related]
10. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections.
Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR
Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056
[TBL] [Abstract][Full Text] [Related]
11. An overview of the safety of isepamicin in adults.
Blum D
J Chemother; 1995 Jun; 7 Suppl 2():87-93. PubMed ID: 8622116
[TBL] [Abstract][Full Text] [Related]
12. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and safety of isepamicin in the treatment of various bacterial infections.
Petrikkos G; Giamarellou H; Tsagaraki C; Pefanis A
J Chemother; 1995 Jun; 7 Suppl 2():161-4. PubMed ID: 8622106
[TBL] [Abstract][Full Text] [Related]
14. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
16. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
17. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series.
Falagas ME; Siempos II; Rafailidis PI; Korbila IP; Ioannidou E; Michalopoulos A
Respir Med; 2009 May; 103(5):707-13. PubMed ID: 19118994
[TBL] [Abstract][Full Text] [Related]
18. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime versus a combination of amikacin and ticarcillin in the treatment of severe infections.
Limson BM; Navarro-Almario E; Litam P; Que E; Kua LT
Clin Ther; 1988; 10(5):589-93. PubMed ID: 2856601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
